G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 113 filers reported holding G1 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $22,000 | -26.7% | 2,920 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $30,000 | -23.1% | 2,920 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $39,000 | -39.1% | 2,920 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $64,000 | -8.6% | 2,920 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $70,000 | +32.1% | 2,920 | 0.0% | 0.00% | +50.0% |
| Q4 2020 | $53,000 | +55.9% | 2,920 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $34,000 | -52.1% | 2,920 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $71,000 | +121.9% | 2,920 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $32,000 | -58.4% | 2,920 | 0.0% | 0.00% | -33.3% |
| Q4 2019 | $77,000 | +14.9% | 2,920 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $67,000 | -25.6% | 2,920 | 0.0% | 0.00% | -25.0% |
| Q2 2019 | $90,000 | +233.3% | 2,920 | +80.5% | 0.00% | +300.0% |
| Q1 2019 | $27,000 | -12.9% | 1,618 | 0.0% | 0.00% | -50.0% |
| Q4 2018 | $31,000 | -63.5% | 1,618 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $85,000 | +21.4% | 1,618 | 0.0% | 0.00% | +33.3% |
| Q2 2018 | $70,000 | +66.7% | 1,618 | +41.9% | 0.00% | +50.0% |
| Q1 2018 | $42,000 | +223.1% | 1,140 | +70.1% | 0.00% | +100.0% |
| Q4 2017 | $13,000 | – | 670 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
| Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
| Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
| 361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
| CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
| Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
| Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
| Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
| HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |